Document is current
Any future updates will be listed below
-
Authors
Calsolaro, Valeria
Matthews, Paul M. https://orcid.org/0000-0002-1619-8328
Donat, Cornelius K.
Livingston, Nicholas R. https://orcid.org/0000-0002-6582-2545
Femminella, Grazia D.
Guedes, Sandra Silva
Myers, Jim
Fan, Zhen
Tyacke, Robin J.
Venkataraman, Ashwin V.
Perneczky, Robert
Gunn, Roger
Rabiner, Eugenii A. https://orcid.org/0000-0003-3612-6687
Gentleman, Steve
Parker, Christine A.
Murphy, Philip S.
Wren, Paul B.
Hinz, Rainer https://orcid.org/0000-0002-7808-9207
Sastre, Magdalena
Nutt, David J. https://orcid.org/0000-0002-1286-1401
Edison, Paul https://orcid.org/0000-0002-6551-2002
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (0000)
Dementia Platform UK (DPUK) NIHR Imperial Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 26 December 2020
Revised: 16 May 2021
Accepted: 8 June 2021
First Online: 15 July 2021
Competing interests
: PE is a consultant to Roche, Pfizer and Novo Nordisk. He has received speaker fees from Novo Nordisk, Pfizer, Nordea, Piramal Life Science. He has received educational and research grants from GE Healthcare, Novo Nordisk, Piramal Life Science/Life Molecular Imaging, Avid Radiopharmaceuticals and Eli Lilly. He is an external consultant to Novo Nordisk and a member of their Scientific Advisory Board. PMM acknowledges consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers’ honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera.
